[1] RUNO J R, LOYD J E. Primary pulmonary hypertension. Lancet, 2003,361(9368):1533-1544. [2] BETKIER-LIPINSKA K, RYCZEK R, KWASIBORSKI P, et al. Pulmonary arterial hypertension: modern diagnostics and therapy--Part 1. Pol Merkur Lekarski, 2013,34(204):355-359. [3] BISHOP D, BAKER N, GANDHI R, et al. Pulmonary arterial hypertension: bridging the gap between efficacy, quality of life, and cost-effectiveness. Formulary, 2010,45(6):190-199. [4] JING Z C, XU X Q, HAN Z Y, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest, 2007,132(2):373-379. [5] D′ALONZO G E, BARST R J, AYRES S M, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med, 1991,115(5):343-349. [6] CONOLE D, SCOTT L J. Riociguat: first global approval. Drugs, 2013,73(17):1967-1975. [7] DOWDALL M. Riociguat recommended by CHMP for approval in the EU for use in two forms of pulmonary hypertension. Future Cardiol, 2014,10(2):163. [8] STASCH J P, PACHER P, EVGENOV O V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation,2011,123(20):2263-2273. [9] GIAID A, SALEH D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med, 1995,333(4):214-221. [10] GARNOCK-J K P. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension. Drugs,2014,74(17):2065-2078. [11] GRIMMINGER F, WEIMANN G, FREY R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J, 2009,33(4):785-792. [12] GHOFRANI H A, GALIE N, GRIMMINGER F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med, 2013,369(4):330-340. [13] GHOFRANI H A, D′ARMINI A M, GRIMMINGER F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med, 2013,369(4):319-329. [14] MEIS T, BEHR J. Riociguat for the treatment of pulmonary hypertension. Expert Opin Pharmacother, 2014,15(16):2419-2427. [15] SCHERMULY R T, STASCH J P, PULLAMSETTI S S, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J, 2008,32(4):881-891. [16] GHOFRANI H A, HOEPER M M, HALANK M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J, 2010,36(4):792-799. [17] FREY R, MUCK W, UNGER S, et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol, 2008,48(8):926-934. [18] BONDERMAN D, GHIO S, FELIX S B, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation, 2013,128(5):502-511. [19] BONDERMAN D, PRETSCH I, STERINGER-MASCHERBAUER R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure(DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest, 2014,146(5):1274-1285. [20] HAUBER H P. Interstitial lung diseases and pulmonary hypertension. Internist(Berl), 2009,50(9):1072, 1074-1076, 1078-1079. [21] COLLARD H R, ANSTROM K J, SCHWARZ M I, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest, 2007,131(3):897-899. [22] GHOFRANI H A, WIEDEMANN R, ROSE F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet, 2002,360(9337):895-900. [23] HOEPER M M, HALANK M, WILKENS H, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J, 2013,41(4):853-860. [24] STAEHLER G, GRUENIG E, HALANK M, et al. The effect of the soluble guanylate cyclase stimulator riociguat on hemodynamics in patients with pulmonary hypertension due to chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2011,183:6127. [25] RUBIN L J, GALIE N, GRIMMINGER F, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study(PATENT-2). Eur Respir J, 2015,45(5):1303-1313. [26] SIMONNEAU G, D′ARMINI A M, GHOFRANI H A, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study(CHEST-2) . Eur Respir J, 2014,45(5):1293-1302. [27] Briefing Document for Cardiovascular and Renal Drugs Advisory Committee. 2013 . http://www. fda. gov/downloads/advisory committees/ committees meeting materials/ drugs/ cardiovascular and renal drugs advisory committee/ucm363543. [28] FREY R, MUCK W, KIRSCHBAUM N, et al. Riociguat(BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol, 2011,51(7):1051-1060. [29] GALIE N, HOEPER M M, HUMBERT M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC) and the European Respiratory Society(ERS), endorsed by the International Society of Heart and Lung Transplantation(ISHLT). Eur Heart J, 2009,30(20):2493-2537. [30] MCLAUGHLIN V V. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev, 2011,20(122):262-269. [31] BARST R J, RUBIN L J, LONG W A, et al. A comparison of continuous intravenous epoprostenol(prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med, 1996,334(5):296-301. [32] MCLAUGHLIN V V, BENZA R L, RUBIN L J, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol, 2010,55(18):1915-1922. [33] OLSCHEWSKI H, SIMONNEAU G, GALIE N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med, 2002,347(5):322-329. [34] SIMONNEAU G, BARST R J, GALIE N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med, 2002,165(6):800-804. [35] GALIE N, OLSCHEWSKI H, OUDIZ R J, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy(ARIES) study 1 and 2. Circulation, 2008,117(23):3010-3019. [36] RUBIN L J, BADESCH D B, BARST R J, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 2002,346(12):896-903. [37] PULIDO T, ADZERIKHO I, CHANNICK R N, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med, 2013,369(9):809-818. [38] GALIE N, BRUNDAGE B H, GHOFRANI H A, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation, 2009,119(22):2894-2903. [39] GALIE N, GHOFRANI H A, TORBICKI A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 2005,353(20):2148-2157. [40] HOEPER M M, BARBERA J A, CHANNICK R N, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol, 2009,54(suppl 1):S85-S96.